Features

Governed Clinical Capabilities

Eight capability areas for hospital medication safety — tenant-authorized, versioned, and deny-by-default. Enabling software gates is not clinical approval.

Drug Reference

Monographs, comparison, and licensed provenance.

Interaction Checker

Multi-drug and allergy checks with severity taxonomy.

Alert Inbox

Lifecycle workflows with override and escalation.

AI Assistant

Cited retrieval with deterministic authority.

Integrations

FHIR, CDS Hooks, HL7, and EIMS boundaries.

Admin & Governance

Rules, content releases, imports, and audit.

Drug Reference and Monographs

Search by brand, generic, ingredient, class, indication, or local formulary code. Open structured monographs with dosing, interactions, monitoring parameters, and evidence-linked references.

Autocomplete, spelling tolerance, synonyms, and recent items
Content version, owner, review date, and print/export controls
Two-drug comparison for formulary and therapeutic decisions

MedEazy CDSS / Drug Reference

Monographs & Search Engine

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Amoxicillin + Clavulanic Acid 500/125 mg

⌘K

Brand match: Augmentin®, Clavam® ✓ Formulary-approved CDSCO-verified

Amoxicillin / Clavulanate

Rx Only

Oral / IV · Beta-lactamase inhibitor combo · National Formulary

CDSCO Verified

Adult Dosage

500 mg q8h (Adult)

Max 1,500 mg/day

Interactions

2 Moderate

Methotrexate, Warfarin

Renal Clearance

eGFR 28 mL/min → Dose adjust

Extend to q12h interval

Monograph v2026.08 · ICMR/CDSCO Guidance Reviewed 15 Jul 2026

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Multi-Drug and Allergy Interaction Checker

Add proposed and active medicines with allergy context. Detect ingredient, class, and duplicate entries with severity, mechanism, management, and evidence level.

Pair deduplication and patient-context modifiers when validated
Source, rule version, and last review date on every result
Save checks to permitted patient cases with audit where enabled

MedEazy CDSS / Alert Engine

Prioritized Clinical Review Queue

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Prioritized Clinical Alerts

Pt: ICU-04 · Bed 02

1 High Risk 1 Moderate 1 Info

High Risk · Critical Stop

Rule v3.1.2 CDSCO/ICMR

Severe Allergy Cross-Sensitivity · Piperacillin / Tazobactam

Documented Penicillin G anaphylaxis on chart. Cross-reactivity risk estimated >15%. Deterministic engine blocked order.

Moderate · DDI Rule v2.4.1 CDSCO

Additive QTc Prolongation · Azithromycin + Ondansetron

Combined ΔQTc > 60ms expected. Baseline ECG recommended.

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Centralized Alert Inbox and Lifecycle

Review patient-specific alerts with severity, rationale, recommended action, uncertainty, and data freshness — without losing work-list context.

Acknowledge, accept, override, defer, escalate, and resolve
Structured override reasons and mandatory notes by policy
Immutable timeline for governance and safety review

MedEazy CDSS / Alert Engine

Prioritized Clinical Review Queue

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Prioritized Clinical Alerts

Pt: ICU-04 · Bed 02

1 High Risk 1 Moderate 1 Info

High Risk · Critical Stop

Rule v3.1.2 CDSCO/ICMR

Severe Allergy Cross-Sensitivity · Piperacillin / Tazobactam

Documented Penicillin G anaphylaxis on chart. Cross-reactivity risk estimated >15%. Deterministic engine blocked order.

Moderate · DDI Rule v2.4.1 CDSCO

Additive QTc Prolongation · Azithromycin + Ondansetron

Combined ΔQTc > 60ms expected. Baseline ECG recommended.

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Antimicrobial Stewardship Workflows

Support restricted-antibiotic review, culture-before-therapy prompts, de-escalation, IV-to-oral conversion, and intervention documentation.

Case queue with assignment and prescriber justification
Protocol variance and duration signals with explicit denominators
AWaRe classification support where approved for deployment

MedEazy CDSS / Antimicrobial (AMS)

Restricted Authorization & Stewardship

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

AMS Restricted Authorization

Order #AMS-8942 · ICU Bed 12

● Active 48h Window

Meropenem 1g IV

Restricted Reserve

q8h Extended Infusion · AWaRe Classification: Reserve

✓ AMS Approved

Indication

Febrile Neutropenia

Culture Status

Pending

AMS Status

Green Status

Therapy Day

Day 3 of 7

⚡

De-escalation Suggestion

Protocol Active

Blood cultures preliminary negative for carbapenem-resistant GNB at 48h. Per hospital AMS protocol and ICMR 2024 guidance, consider step-down to Piperacillin/Tazobactam upon final organism sensitivity.

De-escalation signal IV → Oral review at 72h ICMR AMS 2024 Aligned

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Therapeutic Monitoring and Safety Surveillance

Configurable worklists for drug levels, overdue checks, ADR intake, and medication-error signals — with human review before confirmed events.

Target ranges, trends, last check, and next due date
Causality assessment workflow for ADR reports
Export boundary to pharmacovigilance systems where approved

MedEazy CDSS / Monitoring & TDM

Therapeutic Drug Monitoring Worklist

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Therapeutic Drug Monitoring (TDM) Worklist

1 Critical Trough Alert

Vancomycin Trough Target: 15–20 µg/mL

MRSA Sepsis Protocol · ICU Patient ICU-04

Current: 22.4 µg/mL High

Subtherapeutic (<15) Target Range (15–20 µg/mL) High (>20)

0 µg/mL 15–20 µg/mL (Optimal) ▲ 22.4 µg/mL (Measured)

Repeat level scheduled: Today at 20:00 (Pre-dose 4th maintenance)

Hold 18:00 dose. Re-draw trough at 20:00. Calculate AUC24/MIC (Target 400–600 mg·h/L). Adjust maintenance to 1g q12h.

Tacrolimus (Prograf)

Current: 7.8 ng/mL · Target: 5.0–10.0 ng/mL

✓ Optimal Next check: 3 days

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

AI-Assisted Retrieval and Explanation

Natural-language search over approved, versioned content with sentence-level citations. Explain deterministic rule output without inventing clinical facts.

Retrieval only from tenant-accessible approved sources
Kill switch and graceful non-AI fallback
Never the sole mechanism for critical alert delivery

MedEazy CDSS / Cited AI Assistant

Governed Clinical Knowledge Retrieval

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Clinician Inquiry · Dr. Sharma (Intensivist)

ICU-04

What is the recommended dosing adjustment and monitoring for Meropenem in moderate renal impairment (eGFR 28 mL/min)?

AI Governed AI Response

100% Governed Retrieval

For patients with moderate renal impairment (eGFR 26–50 mL/min), reduce Meropenem dosage to 1g IV every 12 hours. For eGFR 10–25 mL/min, reduce to 500mg IV every 12 hours [ICMR 2024]. Monitor serum creatinine, eGFR, and platelet count twice weekly during extended therapy [CDSCO Label]. Dose adjustment is mandatory prior to 3rd administration to prevent central nervous system toxicity.

[ICMR 2024] ICMR Antimicrobial Guidelines · Sec 4.2 Renal Dosing

[CDSCO Label] Meropenem Prescribing Info · Sec 8 Renal Impairment

⚠ Governance Notice: Deterministic safety rules remain authoritative. AI retrieval is cited and governed for clinical decision support under human supervision.

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Healthcare Interoperability

FHIR R4/R4B mappings, CDS Hooks discovery, HL7 v2 adapter strategy, and EIMS orchestration with provenance for every external result.

SMART on FHIR launch where required by pilot EHR
Webhook ingestion with replay and dead-letter handling
Conflict policy between vendor and local rule output

MedEazy CDSS / Interoperability

FHIR R4 & CDS Hooks Engine

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

EHR / HIS Interoperability & Live CDS Bus

Live Sync Active · 24ms

FHIR MedicationRequest active

R4 REST API hooked · MR-88231

Active

HL7 v2 ADT synchronized

Admissions & Bed stream live · A08

Synced

order-select-hook.json

HTTP 200 OK

{
  "hook": "order-select",
  "hookInstance": "cdss-req-94821",
  "fhirServer": "https://fhir.hospital-ehr.in/r4",
  "context": { "patientId": "PT-94821", "medications": ["MedicationRequest/MR-88231"] },
  "decision": "DOSE_ADJUSTMENT_REQUIRED"
}

FHIR R4 CDS Hooks 1.0 HL7 v2.5.1 SMART on FHIR SNOMED CT LOINC ABDM Aligned

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Administration, Content, and Clinical Governance

Tenant and facility administration with separated duties for rule and content publication, staged imports, and append-only audit search.

Rule simulation, golden cases, and impact preview
Content release author-review-approve-publish-retire workflow
Cross-tenant isolation enforced in queries, jobs, and exports

MedEazy CDSS / Governance & Audit

Immutable Audit & Compliance Log

Workspace

Alert Inbox

Drug Reference

AMS Queue

TDM Worklist

Cited Assistant

Interoperability

CDSS v3.1.2

Immutable Audit & Compliance Log

SHA-256 Verified

Alert Override Logged 14:02:18 IST

User: Dr. Sharma · Reason: Clinical benefit exceeds risk · Patient ICU-04

AMS Order Authorized 13:45:02 IST

Order: Meropenem 1g IV · ID Specialist review recorded

Governed Clinical CDSS Engine · v3.1.2

Synthetic patient context · No PHI

Comparison

More Than a Reference Library

MedEazy combines lookup depth with patient-context checks, governed workflows, and hospital administration — subject to licensing and pilot scope.

How MedEazy compares to reference-only medication lookup tools. Capabilities vary by tenant authorization and pilot scope.
Capability	MedEazy CDSS	Reference-only lookup
Structured monographs with provenance	Yes	Often
Patient-context deterministic checks	Yes	Rarely
Alert inbox with audit lifecycle	Yes	No
Stewardship case and intervention workflow	Yes	No
Therapeutic monitoring worklists	Yes	Limited
Multi-tenant hospital administration	Yes	Varies
EHR / FHIR / CDS Hooks integration path	Yes	Varies
Cited AI over approved content only	Governed	Often ungoverned

See How Capabilities Fit Your Hospital Workflow

Request a demo or explore solutions for pharmacy, stewardship, and clinical governance teams.

Request a Demo View Solutions